# PAS-004 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06299839/  
OnCo record `nct06299839` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.

## Summary

PAS-004 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06299839 by Pasithea Therapeutics Corp., with 83 participants planned, started 2024-02-29. Conditions recorded: RAS Mutation, NF1 Mutation, RAF Mutation and Advanced Solid Tumors. Interventions recorded: PAS-004 Capsules and PAS-004 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06299839
- Phase: 1
- Setting: A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition
- Sponsor: Pasithea Therapeutics Corp.
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT06299839: https://clinicaltrials.gov/study/NCT06299839

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PAS-004](https://onco.cc/drugs/pas-004/)
- companies: [Pasithea Therapeutics](https://onco.cc/companies/pasithea-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06299839.json